15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

查看: 1222|回复: 6
go

ICAR2016 [复制链接]

Rank: 10Rank: 10Rank: 10

现金
20661 元 
精华
帖子
12793 
注册时间
2013-12-29 
最后登录
2024-11-3 
1
发表于 2016-6-13 13:00 |只看该作者 |倒序浏览 |打印
本帖最后由 newchinabok 于 2016-6-13 13:00 编辑

http://c.ymcdn.com/sites/www.isa ... 2016_webApril11.pdf
已有 1 人评分现金 收起 理由
StephenW + 20

总评分: 现金 + 20   查看全部评分

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2016-6-13 19:17 |只看该作者
059
    RNAi-mediated Suppression of Cyclophilins Does Not Inhibit HBV Viral Biomarkers
Andrew Kondratowicz, Ph.D.
1, Nicholas Snead, Ph.D.1, Agnes Jarosz, B.S.1, Amy C.H. Lee, M.S.1, Laurèn Bailey, Ph.D.2, Andrea Cuconati, Ph.D.2, Michael Sofia, Ph.D.2
1Arbutus Biopharma, Corp., Burnaby, BC, Canada;
2Arbutus Biopharma, Inc., Doylestown, Pennsylvania, USA
BACKGROUND:
Approximately 400 million individuals worldwide are infected with Hepatitis B virus (HBV), making it one of the leading causes of
hepatocellular carcinoma and liver disease. Cyclophilins (peptidyl-prolyl isomerases; PPI) are cellular chaperones that are utilized in the life cycle of a
number of human pathogens, including HCV and HIV. Several in vitro
reports have suggested that cyclophilins may serve as an attractive candidate
for therapeutic intervention in the HBV life cycle. Here, we utilize siRNA-based inhibition of PPIA, PPIB, and PPID expression, both in vitro and in vivo,
to further evaluate the therapeutic potential.
METHODS:
We evaluated the in vitro potency of cyclophilin knockdown in HepDE19 cells, which replicates HBV gene expression and antigen production under an inducible system. In parallel, in vivo anti-HBV potential was evaluated in a hydrodynamic injection (HDI) mouse model using lipid nanoparticles (LNP) to deliver cyclophilin-targeting siRNAs to the liver.
RESULTS:
PPIA and PPIB depletion, in the absence of any cytotoxic effects, did not have any effect on HBV gene expression in HepDE19 cells.
Furthermore, potent mRNA knockdown of liver PPIA (95% reduction), PPIB (83% reduction), and PPID (76% reduction) did not inhibit serum or liver HBV
markers in the in vivo HDI mouse model.
CONCLUSION:
The knockdown of three cyclophilin isoforms, individually or in combination simultaneously, failed to have any effect on several different
biomarkers of the HBV lifecycle. Our data does not support further clinical development of cyclophilin inhibitors against HBV.
059
    亲环的RNAi介导的抑制不抑制HBV病毒标志物
安德鲁Kondratowicz,博士
1,尼古拉斯·斯尼德,Ph.D.1,艾格尼丝Jarosz,B.S.1,艾米C.H.李,M.S.1,劳伦·贝利,Ph.D.2,安德烈Cuconati,Ph.D.2,迈克尔·索菲亚,Ph.D.2
1Arbutus生物制药公司,本那比,BC,加拿大;
2Arbutus生物制药公司,宾夕法尼亚州Doylestown,美国
背景:
全球约400万人感染了乙型肝炎病毒(HBV),使得它的主要原因之一
肝细胞癌和肝病。亲环(肽基 - 脯氨酰异构酶; PPI)是被用在一个生命周期蜂窝伴侣
人类病原体,包括HCV和HIV数量。几个体外
报告表明,亲环素可作为一个有吸引力的候选者
在HBV生命周期的治疗干预。这里,我们利用PPIA,PPIB,和PPID表达的基于siRNA的抑制,无论是在体外和体内,
以进一步评估的治疗潜力。
方法:
我们评估了在HepDE19细胞亲环敲低,它复制的诱导型系统下的HBV基因的表达和抗原生产的体外效力。平行地,在体内的抗HBV电位在一个高压注射(HDI)小鼠模型中使用的脂质纳米颗粒(LNP)提供亲环定位的siRNA到肝脏评价。
结果:
PPIA和PPIB枯竭,在没有任何细胞毒性作用,没有在HepDE19细胞对HBV基因表达的任何影响。
此外,有效的mRNA的拦截肝PPIA(减少95%),PPIB(83%降低),和PPID(76%还原)的不抑制血清或肝脏HBV
标记物在体内的HDI小鼠模型。
结论:
三亲环亚型,单独或结合击倒同时,未能有几个不同的任何影响
乙肝病毒生命周期的生物标志物。我们的数据不支持抗HBV亲环蛋白抑制剂的进一步的临床发展。
已有 1 人评分现金 收起 理由
zgct + 3

总评分: 现金 + 3   查看全部评分

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

3
发表于 2016-6-13 19:22 |只看该作者
065
    Neplanocin A Derivatives as Selective Inhibitors of HBV with a Novel Mechanism Of Action
Masaaki Toyama, Ph.D.1, Takayuki Hamasaki, Ph.D.1, Mika Okamoto, M.D., Ph.D.1
, Masanori Baba, M.D., Ph.D.1, Koichi Watashi, Ph.D.2, Takaji Wakita, M.D., Ph.D.2
, Atsuya Yamashita, Ph.D.3, Kohji Moriishi, Ph.D.3, Ashoke Sharon, Ph.D.4
1 Kagoshima University, Kagoshima, Kagoshima, Japan;
2 Department of Virology II, National Institute of Infectious Diseases,
Shinjuku-ku, Tokyo, Japan;
3 University of Yamanashi, tyuhoh-shi, Yamanashi, Japan;
4 Department of Applied Chemistry, Birla Institute of Technology, Mesra, Ranchi, India
Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside analogs, such as lamivudine, entecavir, and tenofovir. Although these
analogs are effective in HBV-infected patients, emergence of drug-resistant mutants during chemotherapy and viral reactivation after treatment
interruption are major concerns in current antiviral agents against HBV. Therefore, it seems still mandatory to identify and develop novel inhibitors of HBV.
We have reported in the previous ICAR that neplanocin A derivatives are novel and selective inhibitors of HBV replication (AR-II-04-26: EC50; 0.77 + 0.23,CC50; > 100 M, MK-III-02-03: EC50; 0.88 + 0.43, CC50; 67.8 + 7.7 M). In this study, we investigated the mechanism of action of these compounds in
primary human hepatocytes. The neplanocin A derivatives could reduce HBsAg and HBeAg levels in culture supernatants of HBV-infected hepatocytes,
but lamivudine and entecavir could not. The compounds also suppressed 3.5 kb pregenome RNA and 2.4/2.1 kb RNA in the infected hepatocytes.
Moreover, they decreased HBV core promoter activity in HepG2 cells transiently transfected with an HBV-expression plasmid. These results suggest that
the neplanocin A derivatives inhibit the expression of HBV RNA from cccDNA. Thus, it is clear that their mechanism of action differs from that of existing
anti-HBV nucleosides.

065
    Neplanocin A衍生物作为选择性HBV抑制剂与新型机构的动作
富山正明,Ph.D.1,孝之滨崎步,Ph.D.1,米卡冈本,医学博士,Ph.D.1
,正德巴巴,医学博士,Ph.D.1,弘一渡,Ph.D.2,鹰二胁田,医学博士,Ph.D.2
,Atsuya山下,Ph.D.3,Kohji Moriishi,Ph.D.3,Ashoke沙龙,Ph.D.4
1鹿儿岛大学,鹿儿岛,鹿儿岛,日本;
病毒学II的2部,传染病研究所,
新宿-ku,东京,日本;
3山梨大学,tyuhoh市,山梨县,日本;
应用化学,技术伯拉研究所,从Mesra,兰契,印度的4部
慢性乙型肝炎病毒(HBV)感染目前与核苷类似物,如拉米夫定,恩替卡韦,和替诺福韦处理。虽然这些
类似物是有效的HBV感染患者,治疗后的化疗和病毒活化过程耐药突变体的出现,
中断是抗HBV目前的抗病毒药物主要关注的问题。因此,似乎仍然是必须确定和开发HBV的新型抑制剂。
我们已经报道在以前是ICAR一个neplanocin衍生物是HBV复制(新颖和选择性抑制剂AR-II-04-26:EC50; 0.77 + 0.23,CC50;> 100M,MK-III-02-03:EC50 ; 0.88 + 0.43,CC50; 67.8 + 7.7M)。在这项研究中,我们研究了这些化合物的作用机制在
原代人肝细胞。该neplanocin A衍生物能减少乙肝病毒感染的肝细胞培养上清液HBsAg和HBeAg的水平,
但拉米夫定和恩替卡韦不能。该化合物还抑制了3.5kb的前基因组RNA和在感染的肝细胞2.4 / 2.1 kb的RNA。
此外,它们在与HBV-表达质粒瞬时转染的HepG2细胞减少HBV核心启动子活性。这些结果表明,
在neplanocin A衍生物抑制HBV RNA的cccDNA的表达。因此,很显然,它们的作用机理不同于现有的不同
抗HBV核苷。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

4
发表于 2016-6-13 20:03 |只看该作者
129
Sequence Independent Endo- and Exo-Ribonuclease Activities of the HBV Ribonuclease H, a New Target for Drug Development
Juan Villa Torrecilla, Ph.D.1, Daniel Pike, B.S.1, Kunjan Patel, B.S.1, Elena Lomonosova, Ph.D.1, Roz Abdulqader, B.S.1, John Tavis, Ph.D.1,Gaofeng Lu, M.D.2
1Saint Louis University, Saint Louis, Missouri, USA;
2Zhengzhou University, Zhengzhou, Henan, China
Hepatitis B Virus replication requires the viral ribonuclease H (RNaseH) to degrade the RNA pregenome after it has been copied into DNA. The RNaseH
has not previously been biochemically characterized despite being a new target for drug discovery.
Pure monomeric HBV RNaseH with dual MBP/His6 tags was obtained following nickel-affinity chromatography when ATP and Mg++ were included in the
buffers to remove copurifying bacterial chaperones.  The RNaseH had wide temperature and pH tolerances.  It required Mg++ for specific cleavage, was
inhibited by Ca++, and lost specificity for RNANA heteroduplexes in Mn++.  The endonucleolytic RNaseH activity required an DNA:RNA heteroduplex >14 basepairs long and had no sequence specificity or positional dependence within the RNA.  The RNaseH could not cut substrates with a bulge or a gap in the DNA in the DNA trand, but it could cut when the DNA strand contained a nick.  The enzyme cut the RNA at multiple positions within the minimal 14 nt heteroduplex, and the cleavage pattern implied that the enzyme may bind to the substrate in both possible orientations.  The RNaseH was also found to have a processive 3’-5’ exoribonuclease activity.  
In silico modeling yielded a plausible model of the RNaseH with the DEDD catalytic motive oriented correctly for Mg++ binding.
These data are consistent with the HBV reverse transcription mechanism that features an initial endoribonucleolytic cut, processive 3’-5’ degradation
of the RNA pregenome, and a sequence-independent terminal RNA cleavage.  These data provide support for our ongoing anti-RNaseH drug discovery
efforts.
29
独立的序列内切和外核糖核酸药物开发的乙肝病毒核糖核酸酶H,新目标的活动
胡安别墅托雷西利亚,Ph.D.1,丹尼尔·派克,BS1,Kunjan帕特尔,BS1,埃琳娜Lomonosova,Ph.D.1,罗兹Abdulqader,BS1,约翰·塔维斯,Ph.D.1,高峰路,MD 2
1Saint圣路易斯大学,圣路易斯,密苏里州,美国;
2Zhengzhou大学,郑州,河南,中国
乙型肝炎病毒复制需要病毒核糖核酸酶H(RNA酶H)以降解RNA前基因组已经被复制到DNA之后。该RNA酶H
先前没有生化表征尽管是用于药物发现的新靶点。
纯单体的HBV RNA酶H的双MBP /的His6标签得到以下的镍亲和层析时ATP和Mg ++的包括在
缓冲区删除copurifying细菌伴侣。该RNA酶H有广泛的温度和pH值公差。它要求Mg ++的特定乳沟,是
以Ca ++抑制,失去了特异性RNA:锰++ DNA异源。该内切RNA酶H活动所需的DNA:RNA异源> 14个碱基对长,有RNA内没有序列特异性或部位的变化。该RNA酶H不能切断与一个凸起或在该DNA trand该DNA的间隙底物,但是当DNA链包含一个缺口它可以切断。酶切割在多个位置的RNA中的最小的14个核苷酸的异源内,并且切割图案暗示酶可以结合到基片在两个可能的取向。该RNA酶H也被发现具有的processive 3'-5'核糖核酸外切酶的活性。
在硅片建模产生的RNA酶H的一个似是而非的模型正确的方向为Mg ++的结合DEDD催化动力。
这些数据都与乙肝病毒反转录机制,其特点是初始核糖核酸内切剪,的processive 3'-5'降解一致
体的RNA前体基因组,和一个序列无关的终端RNA裂解。这些数据为我们正在进行的抗RNA酶H的药物开发提供支持
努力。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

5
发表于 2016-6-13 20:07 |只看该作者
131
Establishment of a Novel HBV cccDNA Reporter Cell Line for High Throughput Screening
Dawei Cai, Ph.D.1, Haitao Guo, Ph.D.1, Xiaohe Wang, M.D.2, Andrea Cuconati, Ph.D.2, Changhua Ji, M.D., Ph.D.3
1Indiana University School of Medicine, Indianapolis, Indiana, USA;
2Baruch S. Blumberg Institute, Hepatitis B Foundation, Doylestown,
Pennsylvania, USA;
3Virology Discovery, Roche Pharma Research and Early Development, Nutley, New Jersey, USA

It is generally acknowledged that the elimination of intrahepatic covalently closed circular DNA (cccDNA) is the ultimate goal for a definite cure of HBV
infection. Due to technical difficulties with direct measurement of cccDNA in a high throughput format, a surrogate marker for cccDNA is needed to set
up high throughput screening (HTS) system for discovery of cccDNA inhibitors. In response to this need, we have previously reported a HepDE19 cell
line which expresses HBV “e antigen” (HBeAg) in a cccDNA-dependent manner. However, the existing assay is not ideal for HTS because the HBeAg
ELISA cross reacts with core antigen (HBcAg), an HBeAg homologue expressed largely from the integrated transgene in HepDE19 cells. Here, we report
a “second generation” cccDNA reporter cell line, namely HepBHAe82 cells, in which an HA epitope was incorporated into HBeAg. In the meantime, we developed a chemiluminescence ELISA (CLIA) for detection of HA-tagged HBeAg with HA antibody serving as capture antibody and HBeAb serving as detection antibody, which eliminates the contamination signal from HBcAg. We also established a HepHA-HBe4 cell line that constitutively expresses HA-HBeAg, which will be used in counter screen to filter out the hits that inhibit the metabolism or secretion of HBeAg. The new cccDNA reporter assay system exhibits high levels of cccDNA and HA-HBeAg production, and high specific readout signals with low noise.  This system is currently used to identify compounds and host factors that regulate cccDNA metabolism and transcription in our laboratory.
131
高通量筛选新型乙肝病毒的cccDNA记者细胞系的建立
张大伟蔡Ph.D.1,海涛郭,Ph.D.1,笑呵呵的王,M.D.2,安德烈Cuconati,Ph.D.2,彰化籍,医学博士,Ph.D.3
医药,印第安纳州印第安纳波利斯,美国1Indiana学院;
2Baruch S. Blumberg的研究所,乙型肝炎基金会,Doylestown的,
宾夕法尼亚州,美国;
3Virology发现,罗氏制药的研究和发展初期,纳特利,新泽西州,美国

人们普遍承认,肝内的消除共价闭合环状DNA(cccDNA的)是用于HBV的一个明确的治疗的最终目标
感染。由于与在高通量形式的cccDNA直接测量技术困难,需要用于cccDNA的一个替代标志设置
向上高通量筛选(HTS)系统的cccDNA抑制剂的发现。针对这一需求,我们先前已经报道​​了HepDE19细胞
该行表示乙肝“e抗原”(大三阳)在cccDNA的依赖性。然而,现有的检测是不理想的HTS因为大三阳
ELISA交叉核心抗原(HBcAg)反应,发生HBeAg同源从HepDE19细胞中的基因整合在很大程度上表达。在这里,我们报告
“第二代”的cccDNA报道细胞系,即HepBHAe82细胞,其中的HA抗原决定基被并入HBeAg的。在此期间,我们开发了化学发光ELISA(CLIA)检测HA标记的HBeAg与HA抗体作为捕获抗体和抗 - HBe作为检测抗体,这消除了从核心抗原污染信号。我们还确定,组成型表达的HA-HBeAg的一个HepHA-HBe4细胞系,其将在计数器屏幕被用于过滤出抑制HBeAg的代谢或分泌的命中。新的cccDNA报告基因分析系统表现出高水平的cccDNA和HA-HBeAg的生产,并具有低噪声高比的读出信号。这个系统是目前用于识别化合物和调节在我们的实验室的cccDNA代谢和转录宿主因素。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

6
发表于 2016-6-13 20:15 |只看该作者
044
   Activation and Induction of Immune Response Genes RIG-I, STING & NOD2 in the Antiviral Activity of SB 92000
in the Woodchuck Model of Chronic Hepatitis B
Manasa Suresh, M.S.1, Kyle Korolowicz, B.S.1, Stefanie Czerwinski, M.S.1, Robin Tucker, M.D.1, Stephan Menne, Ph.D.1, Radhakrishnan Iyer, Ph.D.2
, Seetharamaiyer Padmanabhan, Ph.D.2, Sreerupa Challa, Ph.D.2
, Shenghua Zhou, M.D., Ph.D.2
1Georgetown University, Washington D.C., District of Columbia, USA;
2Spring Bank Pharmaceuticals, Milford, Massachusetts, USA
INTRODUCTION:
SB 9200 is an orally bioavailable dinucleotide that activates the cellular viral sensors RIG-I and NOD2 causing the induction of IFN
signaling cascade for antiviral defense. In efficacy studies in WHV-infected woodchucks, SB 9200 was shown to cause significant reductions of viral DNA
and surface antigens in serum and liver (Menne, et al., EASL 2015). Reported here is the evaluation of the induction and expression of RIG-I, NOD2, and
STING, as well as, IRF3, IRF7 and antiviral cytokines associated with the antiviral activity of SB 9200.
METHODS:
Two groups of five chronically WHV-infected woodchucks were treated orally with SB 9200 at 15 and 30 mg/kg/day for 12 weeks. Both
groups were monitored for 8 weeks post-treatment. Immune responses associated with treatment were determined by changes in RNA transcript levels
of IFN-, , IP-10, IL-6, ISG15 and OAS1 in blood and liver using PCR. Samples from woodchucks were also analyzed for changes in expression levels of
innate immune response genes including RIG-I, NOD2, STING, IRF3, and IRF7 by RT-PCR and immunohistochemistry.
RESULTS:
SB 9200-treatment induced dose-dependent and long-lasting expression of type I IFNs and ISGs, and antiviral cytokines in blood and
liver of woodchucks. SB 9200 treatment also induced the expression of RIG-I, NOD2, STING, IRF3, and IRF7 in liver compared to pretreatment levels.
The expression of all genes was significantly induced during treatment and follow-up.
CONCLUSION:
Our studies demonstrate that anti-viral activity of SB 9200 in woodchucks is associated with activation and induction of the host-immune
response genes.
044
   激活和免疫反应的基因RIG-I,STING与NOD2的诱导SB 92000的抗病毒活性
慢性乙型肝炎的土拨鼠模型
摩纳娑苏雷什,M.S.1,凯尔Korolowicz,B.S.1,孙燕姿Czerwinski,M.S.1,罗宾·塔克,M.D.1,斯蒂芬Menne,Ph.D.1,拉达克里希南艾耶,Ph.D.2
,Seetharamaiyer帕德马纳班,Ph.D.2,Sreerupa Challa,Ph.D.2
,周胜华,医学博士,Ph.D.2
1Georgetown大学,华盛顿,哥伦比亚特区,美国区;
2Spring银行制药,米尔福德,马萨诸塞州,美国
介绍:
SB 9200是一种口服生物可利用的二核苷酸激活蜂窝病毒传感器RIG-I和NOD2导致干扰素的诱导
信号级联的抗病毒防御。在WHV感染土拨鼠疗效研究,SB 9200被证明是导致病毒DNA显著减少
及血清和肝脏(Menne等人,EASL 2015)表面抗原。这里报告是诱导和RIG-I,NOD2的表达的评价,并
斯汀,以及,IRF3,IRF7并用SB 9200的抗病毒活性有关的抗病毒细胞因子。
方法:
五个慢性WHV感染旱獭两组在15和30mg / kg /天用SB 9200口服治疗12周。都
组8周治疗后进行了监测。与治疗相关的免疫应答通过在RNA转录水平的变化来确定
干扰素,,IP-10,IL-6,ISG15和OAS1在血液和肝脏的使用PCR。也分析了在表达水平的变化,从旱獭样品
先天免疫反应基因,包括RIG-I,NOD2,STING,IRF3和IRF7用RT-PCR和免疫组化。
结果:
SB 9200-处理诱导剂量依赖性和长效型的表达我干扰素和的ISG,并在血液的抗病毒细胞因子和
旱獭肝。 SB 9200治疗也诱导RIG-I,NOD2,刺痛,IRF3和IRF7的表达肝相比治疗前水平。
所有基因的表达治疗期间显著诱导和跟进。
结论:
我们的研究表明,在土拨鼠SB 9200的抗病毒活性与活化和诱导相关宿主免疫
反应基因。

Rank: 9Rank: 9Rank: 9

现金
17064 元 
精华
12 
帖子
9399 
注册时间
2007-6-26 
最后登录
2017-11-25 

风雨同舟

7
发表于 2016-6-13 21:05 |只看该作者
马克
日行一善(百善孝为先)
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-15 17:45 , Processed in 0.014954 second(s), 12 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.